Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 402 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early? July 7, 2021 PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer October 29, 2019 Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows September 27, 2019 Introducing our new podcast for researchers February 4, 2022 Load more HOT NEWS An Updated Overview of Estimates for Cancer Incidence and Mortality in... The Growths On This Woman’s Lips Are A Sign That She... FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma ESMO Launches First Congress on Artificial Intelligence and Digital Oncology: A...
